SCH 721015

Drug Profile

SCH 721015

Alternative Names: Instiladrin; rAd-IFN; rAd-IFN/Syn3

Latest Information Update: 07 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schering-Plough
  • Developer FKD Therapies
  • Class Antineoplastics; IFNA2B gene therapies
  • Mechanism of Action Gene transference; IFNA2B expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer

Most Recent Events

  • 01 Nov 2016 MD Anderson Cancer Center completes a phase I trial for BCG-refractory Bladder cancer in USA (NCT01162785)
  • 01 Sep 2016 Phase-III clinical trials in Bladder cancer (Second-line therapy or greater, Late-stage disease) in USA (Intravesicular) (NCT02773849)
  • 12 May 2016 FKD Therapies Oy and Society of Urologic Oncology - Clinical Trials Consortium plan a phase III trial for Bladder cancer (Second-line therapy or greater, Late-stage disease) in USA (Intravesical) (NCT02773849)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top